These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39289042)

  • 21. Corrigendum to "Salidroside postconditioning attenuates ferroptosis-mediated lung ischemia-reperfusion injury by activating the Nrf2/SLC7A11 signaling axis" [Int. Immunopharmacol. 115 (2023) 109731].
    Wang Y; Chen Z; Luo J; Zhang J; Sang AM; Cheng ZS; Li XY
    Int Immunopharmacol; 2023 Apr; 117():110002. PubMed ID: 36925352
    [No Abstract]   [Full Text] [Related]  

  • 22. Corrigendum to "Baccatin III ameliorates bleomycin-induced pulmonary fibrosis via suppressing TGF-β1 production and TGF-β1-induced fibroblasts differentiation" [Int Immunopharmacol. 74 (2019) 105696].
    Nie Y; Zhang D; Qian F; Wu Y
    Int Immunopharmacol; 2022 Mar; 104():108496. PubMed ID: 35016851
    [No Abstract]   [Full Text] [Related]  

  • 23. Corrigendum to "Exosomal miR-127-5p from BMSCs alleviated sepsis-related acute lung injury by inhibiting neutrophil extracellular trap formation" [Int. Immunopharmacol. 123 (2023) 110759].
    Zheng XL; Gu WJ; Zhang F; Zhao FZ; Li LZ; Huang HY; Li LJ; Yi YH; Yin HY; Xu J
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111076. PubMed ID: 37866976
    [No Abstract]   [Full Text] [Related]  

  • 24. Corrigendum to "PAD4 selective inhibitor TDFA protects lipopolysaccharide-induced acute lung injury by modulating nuclear p65 localization in epithelial cells" [Int. Immunopharmacol. 88 (2020) 106923].
    Zhao X; Gu C; Wang Y
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111185. PubMed ID: 37957096
    [No Abstract]   [Full Text] [Related]  

  • 25. Corrigendum to "Methylallyl sulfone attenuates inflammation, oxidative stress and lung injury induced by cigarette smoke extract in mice and RAW264.7 cells" Int Immunopharmacol, volume 59, 2018, 369-374.
    Li A; Liu Y; Zhu X; Sun X; Feng X; Li D; Zhang J; Zhu M; Zhao Z
    Int Immunopharmacol; 2019 Jul; 72():522. PubMed ID: 30922802
    [No Abstract]   [Full Text] [Related]  

  • 26. Corrigendum to "Melatonin inhibits the formation of chemically induced experimental encapsulating peritoneal sclerosis through modulation of T cell differentiation by suppressing of NF-κB activation in dendritic cells" [Int. Immunopharmacol. 126 (2024) 111300].
    Huang SH; Hong ZJ; Chen MF; Tsai MW; Chen SJ; Cheng CP; Sytwu HK; Lin GJ
    Int Immunopharmacol; 2024 Apr; 131():111683. PubMed ID: 38368242
    [No Abstract]   [Full Text] [Related]  

  • 27. Corrigendum to "GTS-21 attenuates ACE/ACE2 ratio and glycocalyx shedding in lipopolysaccharide-induced acute lung injury by targeting macrophage polarization derived ADAM-17" [Int. Immunopharmacol. 129 (2024) 111603].
    Zhu W; Wang F; Hu C; Zhao Q; Zhang D; Wang X; Hu B; Li J
    Int Immunopharmacol; 2024 May; 132():111914. PubMed ID: 38582738
    [No Abstract]   [Full Text] [Related]  

  • 28. Corrigendum to "Salvianolic acid B inhibits hepatic stellate cell activation and liver fibrosis by targeting PDGFRβ" [Int. Immunopharmacol. 122 (2023) 110550].
    Liu F; Li S; Chen P; Gu Y; Wang S; Wang L; Chen C; Wang R; Yuan Y
    Int Immunopharmacol; 2023 Oct; 123():110790. PubMed ID: 37640621
    [No Abstract]   [Full Text] [Related]  

  • 29. Corrigendum to "Epigallocatechin gallate potentially abrogates fluoride induced lung oxidative stress, inflammation via Nrf2/Keap1 signaling pathway in rats: An in-vivo and in-silico study" [Int. Immunopharmacol. 39 (2016) 128-139].
    Shanmugam T; Selvaraj M; Poomalai S
    Int Immunopharmacol; 2020 Mar; 80():106203. PubMed ID: 31983588
    [No Abstract]   [Full Text] [Related]  

  • 30. Corrigendum to "IDO1: An important immunotherapy target in cancer treatment" [Int. Immunopharmacol. 47 (2017) 70-77].
    Li F; Zhang R; Li S; Liu J
    Int Immunopharmacol; 2017 Aug; 49():231. PubMed ID: 28457914
    [No Abstract]   [Full Text] [Related]  

  • 31. Corrigendum to "Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants" [Int. Immunopharmacol. 101(Part B) (2021) 108216].
    He L; Sun B; Guo Y; Yan K; Liu D; Zang Y; Jiang C; Zhang Y; Kong W
    Int Immunopharmacol; 2023 Jun; 119():110260. PubMed ID: 37150708
    [No Abstract]   [Full Text] [Related]  

  • 32. Corrigendum to "Cynapanoside A exerts protective effects against obesity-induced diabetic nephropathy through ameliorating TRIM31-mediated inflammation, lipid synthesis and fibrosis" [Int. Immunopharmacol. 113 (Part B) (2022) 109395].
    Luo J; Tan J; Zhao J; Wang L; Liu J; Dai X; Sun Y; Kuang Q; Hui J; Chen J; Kuang G; Chen S; Wang Y; Ge C; Xu M
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111119. PubMed ID: 37907388
    [No Abstract]   [Full Text] [Related]  

  • 33. Corrigendum to "(E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol alleviates inflammatory responses in LPS-induced mice liver sepsis through inhibition of STAT3 phosphorylation" [Int. Immunopharmacol. 125(Part B) (2023) 111124].
    Kim B; Yu JE; Yeo IJ; Son DJ; Lee HP; Roh YS; Lim KH; Yun J; Park H; Han SB; Hong JT
    Int Immunopharmacol; 2024 Aug; 137():112543. PubMed ID: 38926074
    [No Abstract]   [Full Text] [Related]  

  • 34. Corrigendum to "CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2022 Jan; 102():108194. PubMed ID: 34656428
    [No Abstract]   [Full Text] [Related]  

  • 35. Corrigendum to "Simultaneous blockade of TIGIT and HIF-1α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells" [Int. Immunopharmacol. 101 (2021) 108288].
    Fathi M; Bahmanpour S; Barshidi A; Rasouli H; Kiani FK; Khesht AMS; Izadi S; Rashidi B; Kermanpour S; Mokhtarian R; Karpisheh V; Hassannia H; Mohammadi H; Jalili A; Jadidi-Niaragh F
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113118. PubMed ID: 39271379
    [No Abstract]   [Full Text] [Related]  

  • 36. Corrigendum to 'In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects' [Int. Immunopharmacol. 87 (2020) 106787].
    Ma W; Zhang Y; Yu M; Wang B; Xu S; Zhang J; Li X; Ye X
    Int Immunopharmacol; 2020 Nov; 88():106899. PubMed ID: 32827917
    [No Abstract]   [Full Text] [Related]  

  • 37. Corrigendum to "Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer" [Int. Immunopharmacol. 115 (2023) 109622].
    Momenzadeh N; Hajian S; Shabankare A; Ghavimi R; Kabiri-Samani S; Kabiri H; Hesami-Zadeh K; Shabankareh ANT; Nazaraghay R; Nabipour I; Mohammadi M
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111035. PubMed ID: 37858486
    [No Abstract]   [Full Text] [Related]  

  • 38. Corrigendum to "Pathogenesis of Concanavalin A induced autoimmune hepatitis in mice" [Int. Immunopharmacol. 102 (2022) 108411].
    Hao J; Sun W; Xu H
    Int Immunopharmacol; 2022 Mar; 104():108550. PubMed ID: 35067473
    [No Abstract]   [Full Text] [Related]  

  • 39. Corrigendum to "Different roles of bortezomib and ONX 0914 in acute kidney injury" [Int. Immunopharmacol. 82 (2020) 106259].
    Zhang XZ; Han F; Ding CG; Dou M; Wang YX; Xue WJ; Ding XM; Zheng J; Xu CX; Tian PX
    Int Immunopharmacol; 2024 Jan; 126():111189. PubMed ID: 38012900
    [No Abstract]   [Full Text] [Related]  

  • 40. Corrigendum to "Leukotriene D4 induces cellular senescence in osteoblasts" [Int. Immunopharmacol. 58 (2018)154-159].
    Wei J; Chen S; Guo W; Feng B; Yang S; Huang C; Chu J
    Int Immunopharmacol; 2024 Mar; 129():111673. PubMed ID: 38365537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.